Sakura, Japan

Fusayo Kobayashi

This inventor holds 1 USPTO granted patent. Top assignee: Dainippon Ink and Chemicals, Incorporated. Active years: 1994.


% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 1994

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fusayo Kobayashi: Innovator in Antiviral Agents

Introduction

Fusayo Kobayashi is a notable inventor based in Sakura, Japan. He has made significant contributions to the field of antiviral agents, particularly through his innovative work on tocopheryl oligosaccharides. His research focuses on developing compounds that exhibit improved antiviral action, especially against the Human Immunodeficiency Virus.

Latest Patents

Kobayashi holds a patent for "Sulfated tocopheryl oligosaccharides and antiviral agents including the." This invention relates to novel tocopheryl oligosaccharides, acylated tocopheryl oligosaccharides, and sulfated tocopheryl oligosaccharides. These compounds serve as active ingredients in antiviral agents, demonstrating low toxicities and enhanced efficacy against viral infections.

Career Highlights

Fusayo Kobayashi is associated with Dainippon Ink and Chemicals, Incorporated, where he continues to advance his research. His work has garnered attention for its potential applications in medical science, particularly in the development of antiviral therapies.

Collaborations

Kobayashi has collaborated with notable colleagues, including Kaname Katsuraya and Nahoko Takahashi, who contribute to his research endeavors. Their combined expertise enhances the innovative potential of their projects.

Conclusion

Fusayo Kobayashi's contributions to the field of antiviral agents highlight the importance of innovation in medical research. His work on tocopheryl oligosaccharides represents a significant step forward in the fight against viral infections.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…